MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.575
+0.025
+0.70%
Opening 15:56 11/11 EST
OPEN
3.690
PREV CLOSE
3.550
HIGH
3.720
LOW
3.530
VOLUME
14.63M
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
2.770
MARKET CAP
2.23B
P/E (TTM)
-3.9971
1D
5D
1M
3M
1Y
5Y
1D
Why Recursion Pharmaceuticals Bears Were Right Before The Drop
Simply Wall St · 10h ago
Morgan Stanley's list of AI adoption leaders
Seeking Alpha · 2d ago
Weekly Report: what happened at RXRX last week (1102-1106)?
Weekly Report · 2d ago
Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation
Simply Wall St · 2d ago
Recursion Stock Gets A Lift From Trial Progress And New Board Chair
Simply Wall St · 5d ago
Why Does Recursion Pharmaceuticals (RXRX) New Phase 2 Data And Chair Appointment Matter?
Simply Wall St · 6d ago
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX)
TipRanks · 11/04 13:52
Recursion Pharmaceuticals (RXRX) Stock Faces Q3 Results Cash Burn Question
Simply Wall St · 11/03 23:40
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.